Across TCGA pan-cancer cohorts, PCBP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCBP2 data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCBP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PCBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.294	0.959	<.001	31	view →
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	11	view →
LUAD	DFS	Tertile	II,III,IV	0.811	0.268	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PCBP2 tumor-vs-normal RNA expression · all PCBP2 data types